- Home
- BYAH vs OGEN Comparison
BYAH vs OGEN Comparison
Compare BYAH & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYAH | OGEN |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | China | United States |
| Employees | 41 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.6M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | BYAH | OGEN |
|---|---|---|
| Price | $1.02 | $0.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.7K | ★ 234.3K |
| Earning Date | 03-02-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.11 |
| 52 Week High | $2.77 | $9.16 |
Technical Indicators
Market Signals| Indicator | BYAH | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 39.10 |
| Support Level | $0.11 | N/A |
| Resistance Level | $2.77 | $1.02 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 31.39 | 29.12 |
Price Performance
Historical ComparisonAbout BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.